President Alberto Fernández will hold a video conference today with the AstraZeneca laboratory, which will develop the coronavirus vaccine in Argentina, and participate, under the same modality, of the National Congress of the Federation of Associations of Argentine Health Workers.As officially reported, the representative will communicate, from 11.30, with AstraZeneca’s global CEO Pascal Soriot, who is in charge of the Swedish-English company in charge of developing the active substance of the SARS-CoV-2 vaccine investigated by the University of Oxford in the country’s agenda, Fernandez will receive at the Residence of Olives to Nissan Automotive Executives and maintain a videoconference with the Nissan Latam , Guy Rodriguez, as reported by the Presidency.
At 14 o’clock, meanwhile, the President will participate by videoconference of the National Congress of the Federation of Associations of Workers of The Argentine Health.It is worth remembering that on August 12, Fernández, and the Minister of Health of the Nation, Ginés González García, announced that Argentina will be part of the process of production of the vaccine of the AstraZeneca laboratory, held together with the University of Oxford.Al same time ago, less than a month ago the English educational institution was giving the news that they had taken the next step towards the discovery of a safe, effective and accessible vaccine against the coronavirus; the results of the trial of the combined phases I/II were then published in the scientific journal The Lancet,According to the statements of the officials, the fact of producing the vaccine in the country advances at least one year the time in which the doses necessary for the immunity of the population will be received.
However, the announcement in question also stated that it is estimated that the vaccine will be ready for use in the first half of 2021 and that its cost will be between $3 and $4. In this, the objective shared with Mexico will be to manufacture between 150 and 250 million doses to be distributed throughout Latin America, with the exception of the Federal Republic of Brazil.” We have been told that they expect to be able to carry out a production with a 150-floor and a roof of 250 million doses, calculating that Latin America will need about 230 million doses, not counting Brazil, which has an agreement with another development,” the President said.
In this note: